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Introduction. Dupuytren’s disease (DD) is a fibroproliferative disorder of an unknown etiology manifested by 
a pro gressive contracture of fingers. The basic method of the treatment is surgery. Among non-surgical treatments, 
radiotherapy (RT) represents a relevant method.
The aim of the study was to evaluate the efficacy of palmar fascia irradiation in patients with Dupuytren’s Disease.
Material and methods. The research included a group of 117 patients with Dupuytren’s disease irradiated in the 
Department of Radiotherapy in the Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology in 
Gliwice. Patients’ medical records from the Institute of Oncology in Gliwice and the Provincial Hospital of Orthopedics 
and Trauma Surgery in Piekary Śląskie have been analysed retrospectively.
The following were assessed: smoking history and the subjective evaluation of the effect of the therapy and its side 
effects before irradiation and check-up visits.
All patients were irradiated to a total dose of 21 Gy given in 7 fractions.
Results. After the RT, 35% of patients showed an improvement, in 58% of patients the disease progress stopped, 
whereas 7% of patients reported a deterioration.
During the observation period, 7.5% of patients noted a deterioration of the contracture or the topical condition, in 
35% stagnancy was observed, and 57.5% of patients showed a reduction of the contracture and an improvement 
in the topical condition.
After the RT, 87.5% of patients had no side effects, in 7.5% there was a slight skin erythema, 2.5% had superficial 
epidermis exfoliation, and 2.5% reported dry skin.
Conclusions. The obtained results allow one to conclude that palmar fascia irradiation is an effective method of 
treatment for patients with Dupuytren’s disease and it is characterised by a low proportion of complications.
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Introduction
Dupuytren’s disease is a fibroproliferative disorder of an 
unknown aetiology [1, 2]. It is manifested by a progressive 
contracture of the fingers, which impairs hand function. 
This condition, in spite of its unknown aetiology, has been 
known about for about 400 years. The first reports were 
provided by Felix Platter from Basel around 1614 [3, 4]. He 
believed that this disease was caused by shortening of the 
tendons of the finger flexors. Then, in about 1777, Henry 
Cline proposed fasciotomy as a method of treatment. Yet 
the name of the disease comes from Guillaume Dupuytren, 
who described its course in 1831 [3, 4].
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DD is a relatively rare condition; affecting 1–2% of the 
population. Most frequently, it affects men [1, 3, 5, 6]. The 
palmar fascia is shortened and thickened, which, in conse-
quence, leads to a permanent and irreversible flexed con-
tracture of the fingers [3, 7].
The risk factors comprise genetic predispositions — 
race, gender, age, as well as environmental factors. Genetic 
factors play some role in the occurrence of DD, yet, similar 
to its pathogenesis, they still remain largely unexplained. 
The manner of inheritability seems to be heterogenic, most 
frequently it is dominating autosomal with a variable pen-
etration, whilst more rarely it can be recessive autosomal or 
mitochondrial. Genetic studies showed some relationship 
between DD and chromosomes [6, 8–10]. The aberrations 
of the genes participating in the Wnt/beta-catenin signal-
ling pathway seem to play a key role in the pathogenesis 
of the disease [11].
The probability of occurrence of the disease increases 
with age and is higher among men. Among the environ-
mental risk factors, researchers point to tobacco smoking, 
alcohol, trauma, DM, epilepsy and the use of anti-convulsive 
drugs as well as exposure to vibrations [3, 5–7, 12].
Duputren’s disease is a complex condition with a pato-
mechanism that is largely unknown. The occurrence of con-
tractures is related to the disorders of the connective tissue 
function. Both cells and biochemical substances, such as 
growth factors and the substances involved in the cellular 
signalling pathways, take part in this process [10, 13–15].
Physiologically, the correct remodelling of the extra-
cellular matrix plays a key role in the process of fast and 
effective repair of damaged tissues. At the end of the physi-
ological process of wound healing, myofibroblasts disappear 
as a result of apoptosis, yet once the control of this process 
is impaired, the beneficial processes of remodelling might 
lead to organ deformity and loss of function [13]. 
Within the course of DD there is an uncontrolled and 
excessive proliferation of fibroblasts and the storage of 
collagen, mainly type III and IV, and glycosaminoglycans 
[3, 10, 14]. Molecular mechanisms underlying the disease 
are still poorly explained. One of them is believed to be the 
disorder of metalloproteinases (MMP) and tissue inhibitors 
of metalloproteinases (TIMP) ratio. MMP-2 and MMP-14 
proteases are pointed as having a key function in this pro-
cess, and thus, they might be used as markers or a potential 
therapeutic target of medication [9].
A characteristic feature of DD is the presence of nodules. 
The Fibroblasts, which build the nodules reveal an increased 
response to mechanical strain and larger contractility. This 
is connected with an increase in MMP-1, -2, -9 levels and 
a decrease of TIMP expression [16].
In addition, the role of blood vessels in the pathogene-
sis of DD is suggested. Proliferating cells are in the nearest 
vicinity of the vessels and are located mainly in the myo-
fibroblasts layer. The vicinity of small blood vessels is the 
area with an increased presence of growth factors, which 
stimulate the proliferation, that, in connection with an ad-
vantageous composition of extracellular matrix, provides 
an environment which sustains proliferation [17]. Accord-
ing to recent reports, myofibroblasts play a leading role 
in the patomechanism of tendon contractures [12, 18]. It 
is suggested that calcium plays a key role not only in the 
mechanism of myofibroblast contraction, but also in the 
process of inter-and extracellular signalling [13]. Among 
other signalling disorders, there is also a Wnt/beta-catenin 
signalling disruption [11].
The lesion in DD are located along the lines of longitu-
dinal tensions of the hand [3, 19, 20]. This is caused by the 
shortening of the structure of the palmar fascia. The lesions 
affect most frequently finger 5, 4, 3 and then the thumb and 
index finger [21, 22]. The lesions usually affect both hands, 
yet the symptoms are asymmetrically intensive [23, 24]. As 
a consequence, a permanent finger contracture occurs and, 
sometimes, even a deformity of the metacarpophalangeal 
joints and metacarpophalangeal joints. The course of the 
disease may be divided into three stages: the initial one — 
in which the nodules are dominating, the involution stage 
— the differentiation of the cells to myofibroblasts and the 
residual stage in which the collagen fibres are present [1, 
2, 25, 26].
The basic treatment method is surgical intervention. 
Non-surgical methods of contracture treatment comprise 
pharmacology, ultrasounds, physiotherapy and radiother-
apy (RT). In publications there are also references to exper-
imental methods, such as Clostridium histoliticum collage-
nase injections, although the long-term safety and time 
before the recurrence of the condition after this procedure 
still requires further evaluation [14].
Among the most recent reports, there is a continually 
growing interest in the radiotherapy of non-oncological 
conditions, including DD [27, 28]. The use of irradiation 
and the application of ionising radiation is universally 
known and has become an element of the interdisciplinary 
approach to the treatment of many diseases, including Du-
puytren’s disease [1, 2, 25, 26]. The efficacy of RT depends 
on the stage of the disease and is the highest in the early 
stage [1, 2, 25, 26].
The reports described irradiation with the use of frac-
tional dose of 2–3 Gy of the total dose of 15–21 Gy. The 
two most frequently applied regimes of fractionating the 
irradiation dose were: 7 fractions up to a total dose of 21 Gy 
or 5 fractions up to the total dose of 15 Gy in two series 
[25, 26, 28].
The objective of the work was to evaluate the effi-
ciency and occurring complications after the irradiation of 
the palmar fascia in the patients affected by Dupuytren’s 
disease. 
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Material and methods 
Material
The analysis comprised 117 patients irradiated between 
2011 and 2015 at the Radiotherapy Department in Gliwice. 
The study group comprised 78 men and 39 women with 
Dupuytren’s disease in the nodular or contracture stages 
of DD. The patients included in the study were irradiated 
up to a dose of 21 Gy administered in 7 fractional doses. 
In the process of preparation for treatment, all the patient 
thermoplastic immobilisations were performed in order to 
stabilise the limb as well as computer tomography in order 
to plan the treatment process (Fig. 1 and 2).
The age of the patients varied from 30 to 82 years (mean 
61, median: 62). Before the onset of RT, 35 subjects did 
not report any complaints and oedema was observed in 
7 subjects, 20 subjects reported a limitation of mobility, 
3 patients experienced a sensation of tightness, one patient 
had difficulties in squeezing the hand; whereas 24 subjects 
experienced pain, 9 subjects — numbness, 61.5% had con-
tractures; in 54% patients both hands were affected and 
74% had nodules.
58% of patients had a smoking history and 20% patients 
smoked during treatment. 
84% were not previously (before RT) treated, 1% sub-
jects underwent laser therapy, 13% were surgically treated, 
1% with ultrasounds and in 1% steroid therapy was applied 
in the form of local injections. During RT, the patient did not 
undergo any other therapies.
The study visit at which the effects of RT were eval-
uated took place after diverse periods of time (M = 4.8 
months; SD ± 6.11). The results of the first visit were taken 
into consideration. The shortest time span between the 
end of RT and the visit was one month and the longest 
— 34 months.
Methods
The medical files of the Oncology Institute in Gliwice 
and District Hospital of Orthopedics and Trauma Surgery 
in Piekary Śląskie were analysed. 
The collected data comprised the information from the 
periods before the irradiation and from study visits, smoking 
history, current tobacco use, pain complaints, hand function 
disorders and limitation of mobility, previous treatments 
and prospective complications. With regards to the retro-
spective character of the analysis, it was impossible to apply 
Tubian’s scale, as the majority of patients were not evaluated 
according to this scale during the study visits. The patients 
included in the study were in the early stages of DD, hence 
the evaluation of the efficacy of irradiation in their therapy 
seemed justified. On the basis of the data in the patients’ 
histories, the efficacy of the applied RT was evaluated — 
changes regarding the manual function, the presence of 
contracture and the prospective occurrence of new com-
plaints — complications after treatment. The improvement 
was defined as a decrease in the size of nodules, reduction 
of contracture or the improvement of manual function.
Figure 1. A three-dimensional reconstruction of a hand of the patient stabilised in a therapeutic position 
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The statistical analysis was performed with the t-Student 
test. Also the relationship between smoking (regarded as 
a risk factor) and reported complaints and the presence of 
contractures was analysed. The differences in the disease 
symptoms before and after RT were compared. In total, the 
files of 117 patients were analysed.
Results
The information from at least one visit was available 
in 117 cases. During the analysis it was found that some 
patients failed to turn out for the next visit or appeared at 
a different date than appointed.
Immediately after RT, some improvement was observed 
in 35% cases, in 58% the local condition was stable whilst 
7% of patients reported a deterioration of the local condi-
tion. During the observation period, in 57.5% of cases, an 
improvement of the local condition was observed; in 35% 
of cases — a stagnation of the local condition was seen and 
in 7.5% — a deterioration of the local condition.
In the subjects in whose case a follow-up visit took 
place later (M = 6.6 months), an improvement of the local 
condition was seen more frequently (the difference was 
statistically insignificant: t = –1.73; p = 0.9) than in those 
cases where no improvement was observed (M time period 
to the follow-up visit = 2.86 months).
In 87.5% of subjects there were no skin problems after 
RT, 7.5% had some erythema, 2.5% of patients had superfi-
cial epidermal exfoliation and 2.5% reported palmar dryness. 
The patients in whose cases improvement was observed 
were younger at the moment of discharge (M = 59.3 years; 
SD ± 8.9) than those in whose case no improvement was 
seen (M = 63.7 years; SD ± 10.3).
The comparison of smokers and non-smokers among 
patients with regards to their condition after RT did not 
reveal any significant differences (p > 0.05). This concerned 
both the patients with a smoking history only and current 
active smokers (p > 0.05).
Discussion
With regards to the unknown aetiology and complex 
character of Dupuytren’s disease, its causative treatment 
is currently impossible. The currently applied therapies are 
symptomatic. A leading role in the treatment of DD is still 
played by surgical interventions, yet this way of treatment 
is by no means perfect as surgery is connected with a risk 
of complications — at a level of 20% [3, 29–31]. Both the 
intra-operative complications, such as damage of nerves 
or blood vessels and post-surgical complications (i.e. skin 
necrosis or haematoma) must be taken into consideration 
as well as remote complications, which might occur as 
a result of the lack of rehabilitation or its incorrect man-
agement [3, 30–32].
Apart from the risk of complications, another significant 
problem concerning the treatment of DD is the recurrent 
Figure 2. Dose distribution in the target volume. Frontal section of the patient’s hand
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character of the disease. Even surgery does not exclude the 
possibility of recurrence. In various reports, recurrence is 
present in 26–80% of cases [3, 29–31].
Other methods of DD treatment comprise radiotherapy. 
Although the irradiation of the palmar fascia is not the basic 
treatment approach, it is a generally acknowledged and 
widely applied method, especially in the early stage of DD 
[1, 2, 25, 26]. This method utilises the anti-inflammatory and 
anti-proliferative effect of RT. The majority of subjects within 
the study material were neither operated on nor treated with 
any other methods apart from RT — the patients previously 
treated with other methods, ended their treatment before 
RT. They were referred for RT on account of the lack of any 
progress of previous treatments. Also, the initial evaluation 
of the condition of patients included in the study took place 
after treatment with methods other than RT, hence it was 
the use of RT that contributed to the improvement or the 
lack of deterioration (stagnation) of the health condition 
of the patients.
The results obtained within the study must be regarded 
as partly compliant with the published data concerning 
DD. Both with regards to epidemiology and risk factors, the 
picture was congruent with the reports of other authors 
concerning this issue [5, 6], yet the very occurrence of a given 
risk factor in a given group should not preclude its role in 
the pathogenesis of the disease. Out of the risk factors of 
developing DD mentioned in published data was smoking 
[3, 5–7, 12]. In the analysed material, one half of the subjects 
smoked, yet no significant correlation between smoking 
and the course of the disease or the treatment response 
was found. This concerned both the subjects who were not 
smoking during treatment, but had a smoking history as 
well as current active smokers.
In this study, the evaluation of the efficiency of RT had 
a subjective character. In the majority of subjects, no disease 
progression was observed during the follow-up visit (58% 
of patients), in 35% of patients some improvement of the 
hand function was observed. Radiotherapy of patients with 
DD seems therefore an effective method of treatment. Only 
7% of patients reported some deterioration of the hand 
function after the application of RT. The obtained results 
concerning the efficiency are concordant with the most re-
cently published reports concerning this issue [37]. In these 
patients the contracture was progressing gradually, which 
reduced the hand function or, sometimes, the nodules’ size 
was increasing.
Among other parameters, some slight difference was 
observed between the age of the patients and the re-
sponse to RT. The subjects in whose case some improve-
ment was observed were younger than those where no 
improvement took place. The observed difference seems 
to be too small to draw any conclusions, concerning the 
efficiency of RT in the treatment of DD, as conditioned by 
the age of the patients.
Skin reaction, after irradiation, occurred only in 12.5% of 
patients — in 87.5% of cases no skin lesions were observed, 
which is indicative of a low treatment toxicity.
In spite of a long history of radiotherapy use in the 
treatment of non-oncological diseases, the application of 
irradiation in this group of patients still seems controver-
sial and raises some concerns. The controversies concern 
first of all the risk of occurrence of secondary cancers, in 
particular among younger patients with a longer expected 
survival period. However, the interpretation of this data 
with regards to the differences in the irradiation technique 
with regards to the contemporary clinical practice seems 
quite problematic. Modern radiotherapy methods, applying 
patient stabilisation and precise definition of the target 
on the basis of computed tomography, guarantee a high 
precision of dose application and the protection of healthy 
tissues [33, 34]. Currently there are specific guidelines which 
define indications and irradiation strategies in the treat-
ment of non-oncological diseases [36–38]. In accordance 
with the guidelines of the International Commission on 
Radiological Protection, cancer prevalence in the area of 
ionising radiation increases linearly and amounts to 5.5% 
per 1 Sv dose [39, 40]. In the opinion of Broerse, the risk of 
a secondary cancer after radiotherapy used in the treatment 
of non-oncological diseases in young subjects is low and 
totals 0.3–0.7% [41].
In the analysed group, no cases of secondary cancers 
were observed after the use of irradiation in the treatment.
Conclusions
The obtained results allow for concluding that radio-
therapy of the palmar fascia is an effective method of treat-
ing patients with Dupuytren’s disease, in particular at the 
early stage of the disease; this method is also characterised 
by a low rate of complications. It was also observed that in 
patients with some improvement of the hand function, the 
follow-up visit took place at a later date (about 6 months 
after the treatment). This seems important from the point of 
view of the organisation of follow-up visits after RT.
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